Laboratory Monitoring of Chronic Myelogenous Leukemia Patients on Imatinib Mesylate (Gleevec) Therapy
نویسندگان
چکیده
منابع مشابه
Hematopathology / IMATINIB MESYLATE (GLEEVEC) FOR CHRONIC MYELOID LEUKEMIA Chronic Myeloid Leukemia Following Therapy With Imatinib Mesylate (Gleevec) Bone Marrow Histopathology and Correlation With Genetic Status
We evaluated bone marrow pathologic features and cytogenetic and molecular genetic status of 13 patients with interferon-resistant, chronic-phase chronic myeloid leukemia (CML), treated with imatinib mesylate (Gleevec). All had morphologic evidence of CML in the blood and bone marrow and were positive for bcr-abl by reverse transcriptase–polymerase chain reaction, fluorescence in situ hybridiza...
متن کاملPrognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cytogenetic clonal evolution (CE) is a known poor prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph-positive CML). However, its prognostic relevance in the era of imatinib therapy is unknown. We investigated the independent prognostic relevance of CE in 498 patients with Ph-positive CML treated with imatinib for chronic or accelerated phases. One hundred twe...
متن کاملQuantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
PURPOSE The purpose of our investigation was to evaluate the response and minimal residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic myeloid leukemia (CML) treated with imatinib mesylate. EXPERIMENTAL DESIGN One hundred eighty patients with Philadelphia chromosome (Ph)-positive chronic-phase CML after IFN-alpha failure, treated with imatinib mesylate, h...
متن کاملStrategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Imatinib mesylate was approved for the treatment of chronic myelogenous leukemia more than 5 years ago. This drug enabled us to put a very high percentage of patients into hematologic, cytogenetic, and molecular remission. Some patients were resistant to Imatinib from the onset of the treatment whereas others became resistant after showing an initial response to Imatinib mesylate. Various strat...
متن کاملImatinib Therapy in Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) is a clonal proliferative disease originating from a pluripotential stem cell in which a 9:22 translocation, Philadelphia (Ph) chromosome, results in the production of BCR-ABL fusion protein that has constitutive tyrosine kinase activity and deregulates signal transduction pathways, thus causing leukemia. The natural course of CML is usually triphasic (chronic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Laboratory Medicine
سال: 2004
ISSN: 0007-5027
DOI: 10.1309/3ja2-0weq-8pmt-3jqc